Amylin Pharmaceuticals (AMLN) reported a net loss of 32 cents per share in the fourth quarter of 2009, five cents wider than the Zacks Consensus Estimate of 27 cents. The company had reported a net loss of 37 cents in the year-ago quarter. For the full year 2009, net loss came in at $1.20, narrower than the Zacks Consensus Estimate of $1.22 and the year-ago net loss of $1.95.

Total revenues for the quarter were $185.5 million, relatively unchanged from the year-ago period’s revenues. Quarterly revenues consisted of $184.3 million in product sales and $1.3 million in collaborative revenues, which consist of the amortization of upfront fees received under the company’s collaboration agreements with Eli Lilly (LLY) and Takeda. Full year total revenues declined 1.5% to $758.4 million. Full year revenues included net product sales of $754 million and collaborative revenues of $4.4 million.

From the quarter under discussion, Amylin has started presenting reimbursements received under collaborative agreements for research and development as a reduction of research and development expense. Earlier, these reimbursements used to be presented as revenue under collaborative agreements.

Quarterly product revenues comprised $163.7 million in sales of Byetta and $20.6 million in sales of Symlin. Both Byetta and Symlin revenues declined on a sequential basis. Full year Byetta revenues came in at $667.6 million. Amylin is looking to return Byetta to growth now that it is armed with a US Food and Drug Administration (FDA) approval for the use of the drug as a first-line monotherapy for type II diabetes patients.

Symlin revenues for the full year were $86.4 million. Amylin’s increased promotional effort behind Symlin should help prescription growth for the candidate to rebound. The company could also strike a partnership deal for Symlin in non-US territories in 2010.

Selling, general and administrative (SG&A) expenses for the quarter decreased to $84.2 million from $86.1 million in the year-ago period. The decrease was mainly due to efficiencies driven by the company’s reduced cost structure. Full year SG&A spend declined 12.9% to $343.9 million. We expect the SG&A expenses to increase as the company prepares for the launch of exenatide once-weekly, which is currently under FDA review.

Research and development (R&D) expenses decreased slightly to $50.2 million in the reported quarter from $50.5 million reported in the prior-year period. The decrease primarily reflects savings driven by the completion of the company’s obesity programs, besides efficiencies driven by the company’s reduced cost structure. Full year R&D expenses declined 16.8% to $185.1 million.

Amylin provided financial guidance for 2010, stating that it expects operating loss to improve. Amylin intends to exit 2010 with positive operating cash flow on a sustainable basis, and expects to achieve profitability in 2011.

Going forward, we expect investor focus to remain on Byetta’s performance and the approvability of exenatide once-weekly. Amylin stands to receive a $40 million milestone payment from Eli Lilly on the launch of exenatide once-weekly. A response from the FDA should be out by March 5, 2010. We currently have a Neutral recommendation on Amylin.

Zacks Investment Research

1. (CBST) Cubist Pharmaceuticals Misses EstimatesCubist Pharmaceuticals (CBST) reported earnings per share (EPS) of 38 cents for the fourth quarter...
2. (AMLN) Amylin Pharmaceuticals Impresses in Head-to-HeadAmylin Pharmaceuticals, Inc. (AMLN) recently announced positive results on its once weekly formulation of Byetta...
3. (AMLN) Amylin and Eli Lilly’s Byetta Label RevisedEarlier this month, Amylin (AMLN) and Eli Lilly (LLY) announced that the U.S. Food and...
4. (ARNA) Amylin Pharmaceuticals Strikes First on ObesityAlmost all of the news in the obesity race has been made recently by three...
5. (AMLN) Amylin Pharmaceuticals’ Loss NarrowsAmylin Pharmaceuticals (AMLN) reported a loss of 19 cents per share in the third quarter,...
6. (AMLN) Amylin Amylin Pharmaceuticals Collaborates with BioconYesterday, Amylin Pharmaceuticals, Inc. (AMLN) entered into an exclusive agreement with Indian biotech company Biocon...

Search Posts by Tag: AMLN | Amylin Pharmaceuticals Inc | Eli Lilly & Company | LLY | Biotechnology | Healthcare

RSS Feeds by Tag: AMLN | Amylin Pharmaceuticals Inc | Eli Lilly & Company | LLY | Biotechnology | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author